升糖素市场规模、份额和成长分析（按适应症、给药途径、剂型、最终用户和地区划分）－2026-2033年产业预测

2024 年全球升糖素市场规模为 6.4448 亿美元，预计将从 2025 年的 6.8315 亿美元增长到 2033 年的 10.8884 亿美元，预计在预测期（2026-2033 年）内将以 6% 的复合年增长率。

全球升糖素市场正经历显着成长，这主要得益于糖尿病盛行率的上升以及对有效控制严重低血糖需求的日益增长。急救注射装置的普及和鼻用升糖素製剂的进步提高了患者的用药便利性和治疗效果，从而推动了这一增长。此外，加强对医护人员和病患关于如何快速应对低血糖发作的教育也进一步刺激了市场需求。药物输送系统的持续创新和政府的医疗保健支援措施也促进了市场扩张。然而，高昂的治疗成本、医疗资源匮乏地区对胰高血糖素的认知度低、对副作用的担忧、严格的监管要求以及对低温运输物流的依赖等挑战，仍然是市场渗透和规模化发展的主要障碍。

全球升糖素市场驱动因素

全球糖尿病（尤其是第1型糖尿病）盛行率的不断上升是升糖素市场扩张的主要驱动力。胰岛素依赖型患者时时刻刻面临严重低血糖的风险，需要及时介入。这种迫切的医疗需求推动了包括医院、诊所和居家医疗在内的各种医疗机构对升糖素治疗的需求。随着人们对有效升糖素应对低血糖发作重要性的认识不断提高，为了确保患者安全和有效管理糖尿病相关紧急情况，市场持续显着增长。

限制全球升糖素市场的因素

创新型升糖素给药系统，例如预填充自动注射器和鼻腔粉末，研发和生产成本高昂，这可能成为其广泛应用的障碍。这种经济负担在低收入和中等收入国家尤为突出，高昂的价格会阻碍患者获得这些药物。此外，不断上涨的成本也会影响医疗保健系统和保险公司，阻碍这些先进治疗方法的广泛应用和普及。这些经济限制对全球升糖素市场的整体成长和有效性构成挑战，限制了不同族群患者疗效改善的潜力。

全球升糖素市场趋势

受药物传递系统技术的显着进步推动，全球升糖素市场正处于强劲增长期。稳定的液体製剂、鼻喷雾和自动注射器等创新技术正在革新升糖素的给药方式，提高紧急应变能力和患者依从性。这些进步无需药物復溶，提高了储存稳定性，并实现了便捷给药，使患者在低血糖发作时更容易获得治疗。随着人们越来越关注易用性和可靠性强的用户友好型解决方案，医疗服务提供者和患者对这些先进给药方式的接受度不断提高，预计市场将继续扩张。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

全球升糖素市场规模（按适应症和复合年增长率划分）（2026-2033 年）

• 低血糖
• 糖尿病酮酸症
• 代谢疾病的临床试验

全球升糖素市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 静脉注射
• 皮下注射
• 肌肉内注射

全球升糖素市场规模（依剂型划分）及复合年增长率（2026-2033 年）

• 注射套件
• 液态稳定型自动注射器
• 鼻内粉剂
• 液态稳定管瓶

全球升糖素市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 药局
• 网路药房
• 居家医疗环境

全球升糖素市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Sun Pharmaceuticals Industries
• Zealand Pharma
• Biocon
• KemPharm
• Baxter International
• Sandoz
• Teva Pharmaceuticals Industries
• Reddy's Laboratories
• Mylan
• Pfizer
• Novo Nordisk
• Xeris Pharmaceuticals
• Eli Lilly and Company

结论与建议

Global Glucagon Market size was valued at USD 644.48 Million in 2024 and is poised to grow from USD 683.15 Million in 2025 to USD 1088.84 Million by 2033, growing at a CAGR of 6% during the forecast period (2026-2033).

The global glucagon market is experiencing significant growth, driven by the increasing prevalence of diabetes and the rising need for effective management of severe hypoglycemia. This growth is fueled by the widespread adoption of emergency injectable devices and advancements in nasal glucagon formulations, which enhance patient accessibility and outcomes. Efforts to educate healthcare professionals and patients about prompt responses to hypoglycemic episodes are further amplifying market demand. Additionally, continuous innovations in drug delivery systems and supportive government healthcare initiatives contribute to the market's expansion. However, challenges such as high treatment costs, limited awareness in underserved regions, apprehensions regarding side effects, and stringent regulatory requirements, alongside dependence on cold-chain logistics, present substantial barriers to market penetration and scalability.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Glucagon market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Glucagon Market Segments Analysis

Global Glucagon Market is segmented by Indication, Route of Administration, Formulation, End-User and region. Based on Indication, the market is segmented into Hypoglycemia, Diabetic Ketoacidosis and Metabolic Disease Trials. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous and Intramuscular. Based on Formulation, the market is segmented into Injectable Kits, Liquid Stable Autoinjectors, Nasal Powder and Liquid Stable Vials. Based on End-User, the market is segmented into Hospitals, Clinic, Drug Stores, Online Pharmacies and Home Care Setting. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Glucagon Market

The rising prevalence of diabetes, particularly type 1 diabetes, worldwide significantly propels the expansion of the glucagon market. Individuals reliant on insulin are at constant risk of severe hypoglycemia, necessitating prompt intervention. This urgent healthcare requirement heightens the demand for glucagon treatments in various settings, including hospitals, clinics, and homecare environments. As awareness grows regarding the critical need for effective glucagon responses to hypoglycemic episodes, the market continues to experience substantial growth, driven by the necessity to ensure patient safety and effective management of diabetes-related emergencies.

Restraints in the Global Glucagon Market

The development and production of innovative glucagon delivery systems, like prefilled autoinjectors and nasal powders, entails significant costs, which can be a barrier to their widespread adoption. This financial burden is particularly pronounced in low- and middle-income countries, where high prices may deter their utilization. Moreover, the escalation in costs impacts healthcare systems and insurance providers, consequently hindering the broader distribution and accessibility of these advanced treatment options. Such economic constraints pose a challenge to the overall growth and efficacy of the global glucagon market, limiting its potential to improve patient outcomes across diverse demographics.

Market Trends of the Global Glucagon Market

The Global Glucagon market is witnessing a robust growth trajectory, driven by significant technological advancements in drug delivery systems. Innovations such as liquid-stable formulations, nasal sprays, and autoinjectors are revolutionizing how glucagon is administered, enhancing emergency response and patient compliance. These advancements eliminate the necessity for reconstitution, improve shelf stability, and facilitate straightforward administration, making it more accessible for patients during hypoglycemic episodes. With an increasing focus on user-friendly solutions that prioritize ease of use and reliability, the market is set for continued expansion as healthcare providers and patients alike embrace these cutting-edge delivery methods.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Glucagon Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Hypoglycemia
• Diabetic Ketoacidosis
• Metabolic Disease Trials

Global Glucagon Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Subcutaneous
• Intramuscular

Global Glucagon Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Injectable Kits
• Liquid Stable Autoinjectors
• Nasal Powder
• Liquid Stable Vials

Global Glucagon Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinic
• Drug Stores
• Online Pharmacies
• Home Care Setting

Global Glucagon Market Size & CAGR (2026-2033)

• North America (Indication, Route of Administration, Formulation, End-User)
  • US
  • Canada
• Europe (Indication, Route of Administration, Formulation, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Indication, Route of Administration, Formulation, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Indication, Route of Administration, Formulation, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Indication, Route of Administration, Formulation, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Sun Pharmaceuticals Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zealand Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KemPharm
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xeris Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations